NASDAQ:PXMD PaxMedica (PXMD) Stock Price, News & Analysis $0.28 +0.04 (+16.67%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.21▼$0.3150-Day Range$0.21▼$0.3652-Week Range$0.20▼$12.92Volume201,140 shsAverage Volume1.12 million shsMarket Capitalization$2.18 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get PaxMedica alerts: Email Address Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.I have uncovered a bombshell that changes everything… and threatens everything. About PaxMedica Stock (NASDAQ:PXMD)PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.Read More PXMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PXMD Stock News HeadlinesMay 15, 2024 | globenewswire.comPaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101May 14, 2024 | investorplace.comPXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024July 27, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...May 7, 2024 | markets.businessinsider.comPaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory StrategyMay 7, 2024 | finance.yahoo.comPaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory StrategyMay 3, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDAApril 26, 2024 | finance.yahoo.comPaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell PodcastApril 25, 2024 | theglobeandmail.comUrgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in MalawiJuly 27, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...April 25, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDAApril 23, 2024 | globenewswire.comPaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101April 18, 2024 | finanznachrichten.dePaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping SicknessApril 12, 2024 | finanznachrichten.dePaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA SubmissionApril 12, 2024 | markets.businessinsider.comNasdaq Down 300 Points; BlackRock Posts Upbeat EarningsApril 12, 2024 | msn.comPenny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock RalliesApril 12, 2024 | investorplace.comWhy Is PaxMedica (PXMD) Stock Up 93% Today?April 12, 2024 | investorplace.comWhy Is PaxMedica (PXMD) Stock Up 93% Today?April 11, 2024 | msn.comPaxMedica shares soar 125% post-market on drug updateSee More Headlines Receive PXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PaxMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PXMD CUSIPN/A CIK1811623 Webwww.paxmedica.com Phone914-987-2876FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+971.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,151.77% Return on Assets-428.27% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio2.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book0.61Miscellaneous Outstanding Shares7,780,000Free Float7,702,000Market Cap$2.18 million OptionableNot Optionable Beta-0.51 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Howard J. Weisman (Age 64)CEO & Chairman Comp: $717.2kMr. Stephen Douglas Sheldon (Age 44)CFO & COO Comp: $450.85kDr. David W. Hough M.D. (Age 66)Chief Medical Officer Comp: $87.5kKey CompetitorsGalera TherapeuticsNASDAQ:GRTXXenetic BiosciencesNASDAQ:XBIOTenax TherapeuticsNASDAQ:TENXNotable LabsNASDAQ:NTBLGraybug VisionNASDAQ:GRAYView All CompetitorsInsidersHoward J WeismanSold 372 sharesTotal: $174.84 ($0.47/share)Karen LarochelleSold 78 sharesTotal: $37.44 ($0.48/share)Howard J WeismanSold 162 sharesTotal: $166.86 ($1.03/share)Michael DerbySold 185 sharesTotal: $190.55 ($1.03/share)John F CoelhoSold 12 sharesTotal: $12.24 ($1.02/share)View All Insider Transactions PXMD Stock Analysis - Frequently Asked Questions How have PXMD shares performed this year? PaxMedica's stock was trading at $0.7570 on January 1st, 2024. Since then, PXMD stock has decreased by 63.0% and is now trading at $0.28. View the best growth stocks for 2024 here. How were PaxMedica's earnings last quarter? PaxMedica, Inc. (NASDAQ:PXMD) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.07. When did PaxMedica's stock split? Shares of PaxMedica reverse split on the morning of Tuesday, October 31st 2023. The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did PaxMedica IPO? PaxMedica (PXMD) raised $9 million in an initial public offering (IPO) on Friday, August 26th 2022. The company issued 1,600,000 shares at $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. acted as the underwriters for the IPO. How do I buy shares of PaxMedica? Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PXMD) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PaxMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PaxMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
